This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Centene Corporation is a well-diversified, multi-national healthcare company that primarily provides a set of services to the government sponsored healthcare programs. The company serves the under-insured and uninsured individuals through member-focused services. It is also engaged in providing education and outreach programs to inform and assist members in accessing quality, appropriate healthcare services. Centene is now a $100-billion plus enterprise catering healthcare services to more than 24 million members across 50 states. The recent acquisition of WellCare Health leveraged the company’s position as the largest Medicaid managed care organization in the country. The combined entity now has 22 million members. In 2019, the company retained its market-leading position nationwide, serving 1.8 million exchange members across 20 states at the year-end.
ResMed (RMD) Q1 Earnings In Line, Operating Margin Falls
by Zacks Equity Research
ResMed (RMD) continues to increase its access to semiconductor communications chips.
Amedisys (AMED) Q3 Earnings Miss Estimates, Guidance Cut
by Zacks Equity Research
Within Amedisys (AMED) Home Health and Hospice, the reinstatement of sequestration reduces growth in Q3.
Edwards Lifesciences (EW) Q3 Earnings Miss, Margins Rise
by Zacks Equity Research
Edwards Lifesciences (EW) continues to register strong momentum in TMTT on a portfolio of differentiated therapies, positive pivotal trial results and favorable real-world clinical outcomes.
Bio-Rad (BIO) Q3 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Bio-Rad's (BIO) third-quarter revenues decline mainly as a result of lower COVID-related sales compared with the year-ago period.
Molina Healthcare (MOH) Q3 Earnings Top, 2022 EPS View Up
by Zacks Equity Research
Molina Healthcare's (MOH) third-quarter results reflect an expanding customer base within its Medicare and Medicaid businesses. Management hikes 2022 adjusted EPS guidance to a minimum of $17.75.
LabCorp (LH) Misses Q3 Earnings Estimates, Updates Guidance
by Zacks Equity Research
LabCorp's (LH) organic revenues decline significantly, mainly due to major decrease in COVID-19 PCR and antibody testing sales.
Merit Medical (MMSI) Q3 Earnings Beat, FY22 View Revised
by Zacks Equity Research
Merit Medical (MMSI), in the third quarter, benefits from revenue growth in both its segments and the majority of product categories within its Cardiovascular unit.
Is Centene (CNC) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Centene (CNC) and EDAP TMS S.A. (EDAP) have performed compared to their sector so far this year.
West Pharmaceutical (WST) Q3 Earnings Miss, FY22 View Revised
by Zacks Equity Research
West Pharmaceutical's (WST) third-quarter results reflect sustained growth in non-COVID-19 demand amid dismal overall performance.
Universal Health (UHS) Q3 Earnings Top on Better Patient Volumes
by Zacks Equity Research
Universal Health's (UHS) third-quarter results reflect growing patient admissions at its segments. However, margins are hurt by escalated labor costs.
Centene (CNC) Q3 Earnings Top on Medicaid Arm, Revenues Rise Y/Y
by Zacks Equity Research
Centene's (CNC) third-quarter results reflect solid membership growth within its Medicaid and Medicare businesses. Management currently expects adjusted EPS within $5.65-$5.75 for 2022.
Centene (CNC) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Centene (CNC) delivered earnings and revenue surprises of 6.56% and 1.08%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Centene (CNC) to Post Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Centene's (CNC) third-quarter results are likely to reflect higher premiums and contract wins enjoyed by its Medicaid business, partly offset by escalating operating expenses.
Centene (CNC) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Centene (CNC) closed at $75.72 in the latest trading session, marking a +0.53% move from the prior day.
UnitedHealth (UNH) Beats on Q3 Earnings, Ups 2022 EPS View
by Zacks Equity Research
UnitedHealth's (UNH) third-quarter results were supported by membership growth and strong Optum performance.
Centene (CNC) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Centene (CNC) closed at $75.26, marking a +1.26% move from the previous day.
Cigna (CI) to Offer Low-Cost Health Plans in 11 Texas Counties
by Zacks Equity Research
Cigna (CI) expects the 2023 Open Enrollment Period to start on Nov 1 for Texas residents.
HCA Healthcare (HCA) Eyes 3 Hospital Divestments for $150M
by Zacks Equity Research
The divestment by HCA Healthcare (HCA) is likely to leave LCMC Health and Ochsner Health as the two major hospital care providers in the New Orleans region.
Zacks.com featured highlights include US Foods Holding, Signet Jewelers, Centene, Grief and HF Sinclair
by Zacks Equity Research
US Foods Holding, Signet Jewelers, Centene, Grief and HF Sinclair have been highlighted in this Screen of The Week article.
5 Low Price-to-Book Stocks to Buy in October
by Kinjel Shah
The P/B ratio helps to identify low-priced stocks that have high growth prospects. US Foods Holding Corp. (USFD), Signet Jewelers (SIG), Centene Corporation (CNC), Grief (GEF) and HF Sinclair Corporation (DINO) are some such stocks.
4 Low Price-to-Cash Flow Stocks to Shield From a Volatile Market
by Sumit Singh
Value investing is essentially about selecting stocks that are usually cheap but fundamentally sound. Greif (GEF), Unum (UNM), Centene (CNC) and MaxLinear (MXL) boast low P/CF ratios.
Encompass Health (EHC), Piedmont Tie Up to Better Serve Georgia
by Zacks Equity Research
Encompass Health (EHC) collaborates with Piedmont to construct a 40-bed inpatient rehabilitation hospital in Georgia to serve the healthcare needs of the Georgian communities more effectively.
Why Centene (CNC) Could Beat Earnings Estimates Again
by Zacks Equity Research
Centene (CNC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
UnitedHealth (UNH) Grows on Optum Strength, Cost Woes Stay
by Zacks Equity Research
UnitedHealth's (UNH) health service business, Optum, is becoming increasingly valuable and is crucial to the company's diversification strategy.
Cigna's (CI) New Pathwell Suite to Boost Efficiency, Lower Cost
by Zacks Equity Research
Cigna (CI) expects to bump up its Pathwell suite's availability throughout the next year.